What's in ACADIA PHARMS INC's pipeline?

ACADIA PHARMS INC has 2 drugs in our index: 2 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with ACADIA PHARMS INC's portfolio?

Top competitors by shared drug class: Johnson & Johnson, Sunovion Pharms Inc.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/acadia-pharms-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

ACADIA PHARMS INC — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ACADIA PHARMS INC pipeline: 2 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 0 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Daybue	TROFINETIDE	marketed			Other	2023-01-01
Nuplazid	PIMAVANSERIN	marketed	Atypical Antipsychotic	5-hydroxytryptamine receptor 2A	Neuroscience	2016-01-01

Therapeutic area mix

Neuroscience · 1
Other · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Johnson & Johnson · 1 shared drug class
Sunovion Pharms Inc · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for ACADIA PHARMS INC:

Cite this brief

Drug Landscape (2026). ACADIA PHARMS INC — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/acadia-pharms-inc. Accessed 2026-06-10.